{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:21:03Z","timestamp":1788186063258,"version":"build-2803163510"},"reference-count":114,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although interstitial lung disease accounts for the majority of deaths of patients with systemic sclerosis, treatment options for this manifestation of the disease are limited. Few high-quality, randomized, controlled trials exist for systemic sclerosis\u2013related interstitial lung disease, and historically, studies have favored the use of cyclophosphamide. However, the benefit of cyclophosphamide for this disease is tempered by its complex adverse event profile. More recent studies have demonstrated the effectiveness of mycophenolate for systemic sclerosis\u2013related interstitial lung disease, including Scleroderma Lung Study II. This review highlights the findings of this study, which was the first randomized controlled trial to compare cyclophosphamide with mycophenolate for the treatment of systemic sclerosis\u2013related interstitial lung disease. The results reported in this trial suggest that there is no difference in treatment efficacy between mycophenolate and cyclophosphamide; however, mycophenolate appears to be safer and more tolerable than cyclophosphamide. In light of the ongoing advances in our understanding of the pathogenic mechanisms underlying interstitial lung disease in systemic sclerosis, this review also summarizes novel treatment approaches, presenting clinical and preclinical evidence for rituximab, tocilizumab, pirfenidone, and nintedanib, as well as hematopoietic stem cell transplantation and lung transplantation. This review further explores how reaching a consensus on appropriate study end points, as well as trial enrichment criteria, is central to improving our ability to judiciously evaluate the safety and efficacy of emerging experimental therapies for systemic sclerosis\u2013related interstitial lung disease.<\/jats:p>","DOI":"10.1513\/annalsats.201606-426fr","type":"journal-article","created":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T12:28:24Z","timestamp":1472128104000},"page":"2045-2056","source":"Crossref","is-referenced-by-count":71,"title":["Treatment of Systemic Sclerosis\u2013related Interstitial Lung Disease: A Review of Existing and Emerging Therapies"],"prefix":"10.1093","volume":"13","author":[{"given":"Elizabeth R.","family":"Volkmann","sequence":"first","affiliation":[{"name":"Department of Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P.","family":"Tashkin","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,11,1]]},"reference":[{"key":"2026020502573293900_bib1","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2026020502573293900_bib2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026020502573293900_bib3","first-page":"1789","article-title":"High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis","volume":"33","author":"Launay","year":"2006","journal-title":"J Rheumatol"},{"key":"2026020502573293900_bib4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1465-9921-6-96","article-title":"Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis","volume":"6","author":"De Santis","year":"2005","journal-title":"Respir Res"},{"key":"2026020502573293900_bib5","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1164\/rccm.2106012","article-title":"Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome","volume":"165","author":"Bouros","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502573293900_bib6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/art.11113","article-title":"Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies","volume":"49","author":"Reveille","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2026020502573293900_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"2026020502573293900_bib8","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/art.1780370903","article-title":"Severe restrictive lung disease in systemic sclerosis","volume":"37","author":"Steen","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2026020502573293900_bib9","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/art.11073","article-title":"Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population","volume":"48","author":"Mayes","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2026020502573293900_bib10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/s-2007-985610","article-title":"Pulmonary function tests in connective tissue disease [review]","volume":"28","author":"Wells","year":"2007","journal-title":"Semin Respir Crit Care Med"},{"key":"2026020502573293900_bib11","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1148\/radiol.2322031223","article-title":"CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia","volume":"232","author":"Desai","year":"2004","journal-title":"Radiology"},{"key":"2026020502573293900_bib12","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/art.22696","article-title":"Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis\u2013associated interstitial lung disease are not predictive of disease progression","volume":"56","author":"Goh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2026020502573293900_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1164\/rccm.200705-655OC","article-title":"Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease","volume":"177","author":"Strange","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502573293900_bib14","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","article-title":"Severe organ involvement in systemic sclerosis with diffuse scleroderma","volume":"43","author":"Steen","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2026020502573293900_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/ard.62.2.146","article-title":"Predictors of end stage lung disease in a cohort of patients with scleroderma","volume":"62","author":"Morgan","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2026020502573293900_bib16","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/art.22099","article-title":"Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline","volume":"55","author":"Plastiras","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2026020502573293900_bib17","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2026020502573293900_bib18","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502573293900_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/rheumatology\/kes289","article-title":"Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis\u2013related interstitial lung disease","volume":"52","author":"Moore","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"2026020502573293900_bib20","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1002\/art.30467","article-title":"Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group","volume":"63","author":"Khanna","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2026020502573293900_bib21","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1186\/ar3125","article-title":"Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort","volume":"12","author":"Assassi","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2026020502573293900_bib22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3899\/jrheum.120725","article-title":"Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis","volume":"40","author":"De Lauretis","year":"2013","journal-title":"J Rheumatol"},{"key":"2026020502573293900_bib23","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/acr.21968","article-title":"Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026020502573293900_bib24","first-page":"S742","article-title":"Plasma MCP-1 and IL-10 levels predict long-term progression of interstitial lung disease in patients with early systemic sclerosis [abstract]","volume":"65","author":"Wu","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2026020502573293900_bib25","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1183\/09031936.00004711","article-title":"Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis","volume":"38","author":"Tiev","year":"2011","journal-title":"Eur Respir J"},{"key":"2026020502573293900_bib26","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1183\/09031936.00131713","article-title":"Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis","volume":"43","author":"Schupp","year":"2014","journal-title":"Eur Respir J"},{"key":"2026020502573293900_bib27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"van Bon","year":"2014","journal-title":"N Engl J Med"},{"key":"2026020502573293900_bib28","first-page":"1112","article-title":"Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis","volume":"31","author":"Yanaba","year":"2004","journal-title":"J Rheumatol"},{"key":"2026020502573293900_bib29","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1002\/art.39405","article-title":"Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease","volume":"67","author":"Suliman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026020502573293900_bib30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11926-014-0411-1","article-title":"Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease","volume":"16","author":"Akter","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"2026020502573293900_bib31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrrheum.2011.149","article-title":"Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities","volume":"8","author":"Bhattacharyya","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"2026020502573293900_bib32","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3899\/jrheum.080633","article-title":"Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma","volume":"36","author":"Hant","year":"2009","journal-title":"J Rheumatol"},{"key":"2026020502573293900_bib33","first-page":"1933","article-title":"Early pulmonary involvement in systemic sclerosis assessed by technetium-99m-DTPA clearance rate","volume":"35","author":"Fanti","year":"1994","journal-title":"J Nucl Med"},{"key":"2026020502573293900_bib34","doi-asserted-by":"crossref","first-page":"L525","DOI":"10.1152\/ajplung.00163.2007","article-title":"TGF-\u03b2\u2013induced EMT: mechanisms and implications for fibrotic lung disease","volume":"293","author":"Willis","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026020502573293900_bib35","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/BOR.0b013e32833ddcc9","article-title":"Recent advances in pulmonary fibrosis: implications for scleroderma","volume":"22","author":"Homer","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"2026020502573293900_bib36","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1172\/JCI116015","article-title":"Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4","volume":"90","author":"Postlethwaite","year":"1992","journal-title":"J Clin Invest"},{"key":"2026020502573293900_bib37","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1002\/art.22927","article-title":"Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis","volume":"56","author":"Parel","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2026020502573293900_bib38","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/1529-0131(199906)42:6<1168::AID-ANR13>3.0.CO;2-L","article-title":"Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis","volume":"42","author":"Atamas","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2026020502573293900_bib39","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1186\/ar3486","article-title":"Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease","volume":"13","author":"Truchetet","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2026020502573293900_bib40","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jdermsci.2008.01.001","article-title":"Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?","volume":"50","author":"Murata","year":"2008","journal-title":"J Dermatol Sci"},{"key":"2026020502573293900_bib41","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/jid.2009.318","article-title":"A TGF\u03b2-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity","volume":"130","author":"Sargent","year":"2010","journal-title":"J Invest Dermatol"},{"key":"2026020502573293900_bib42","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/1529-0131(199811)41:11<2039::AID-ART20>3.0.CO;2-1","article-title":"Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts","volume":"41","author":"Chizzolini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"2026020502573293900_bib43","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.autrev.2010.09.016","article-title":"Fibrosis and immune dysregulation in systemic sclerosis","volume":"10","author":"Chizzolini","year":"2011","journal-title":"Autoimmun Rev"},{"key":"2026020502573293900_bib44","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/ar4230","article-title":"Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells","volume":"15","author":"Gilbane","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2026020502573293900_bib45","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2174\/187152812800959013","article-title":"Interstitial lung disease in systemic sclerosis: pathophysiology, current and new advances in therapy","volume":"11","author":"Jain","year":"2012","journal-title":"Inflamm Allergy Drug Targets"},{"key":"2026020502573293900_bib46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11926-009-0016-2","article-title":"Current concepts in disease-modifying therapy for systemic sclerosis\u2013associated interstitial lung disease: lessons from clinical trials","volume":"11","author":"Au","year":"2009","journal-title":"Curr Rheumatol Rep"},{"key":"2026020502573293900_bib47","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7","article-title":"High-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial","volume":"42","author":"Clements","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2026020502573293900_bib48","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/anr.1780320512","article-title":"Immunosuppression with chlorambucil, versus placebo, for scleroderma: results of a three-year, parallel, randomized, double-blind study","volume":"32","author":"Furst","year":"1989","journal-title":"Arthritis Rheum"},{"key":"2026020502573293900_bib49","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1055\/s-2006-957335","article-title":"Usual interstitial pneumonia","volume":"27","author":"Lynch","year":"2006","journal-title":"Semin Respir Crit Care Med"},{"key":"2026020502573293900_bib50","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2026020502573293900_bib51","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"2026020502573293900_bib52","first-page":"838","article-title":"Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease","volume":"20","author":"Silver","year":"1993","journal-title":"J Rheumatol"},{"key":"2026020502573293900_bib53","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-132-12-200006200-00004","article-title":"Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis","volume":"132","author":"White","year":"2000","journal-title":"Ann Intern Med"},{"key":"2026020502573293900_bib54","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.09-0108","article-title":"Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the Scleroderma Lung Study","volume":"136","author":"Goldin","year":"2009","journal-title":"Chest"},{"key":"2026020502573293900_bib55","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00330-011-2223-2","article-title":"Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide","volume":"21","author":"Kim","year":"2011","journal-title":"Eur Radiol"},{"key":"2026020502573293900_bib56","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502573293900_bib57","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/rheumatology\/kel244","article-title":"Mycophenolate mofetil in diffuse cutaneous systemic sclerosis: a retrospective analysis","volume":"46","author":"Nihtyanova","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"2026020502573293900_bib58","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/rheumatology\/kep295","article-title":"A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis","volume":"48","author":"Derk","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2026020502573293900_bib59","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1378\/chest.06-2861","article-title":"Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease","volume":"133","author":"Gerbino","year":"2008","journal-title":"Chest"},{"key":"2026020502573293900_bib60","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s10067-011-1823-1","article-title":"Effect of mycophenolate sodium in scleroderma-related interstitial lung disease","volume":"30","author":"Sime\u00f3n-Aznar","year":"2011","journal-title":"Clin Rheumatol"},{"key":"2026020502573293900_bib61","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0012-3692(15)50949-5","article-title":"Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease\u2013related interstitial lung disease","volume":"130","author":"Swigris","year":"2006","journal-title":"Chest"},{"key":"2026020502573293900_bib62","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.rmed.2007.07.021","article-title":"Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease","volume":"102","author":"Zamora","year":"2008","journal-title":"Respir Med"},{"key":"2026020502573293900_bib63","first-page":"708","author":"Tashkin","year":"2016"},{"key":"2026020502573293900_bib64","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1136\/annrheumdis-2015-eular.3483","article-title":"PHAROS Investigators. Mycophenolate mofetil (MMF) use in scleroderma patients with pulmonary hypertension: FVC, outcomes, and survival: observations from the Pulmonary Hypertension Recognition and Outcomes in Scleroderma (Pharos) cohort [abstract]","volume":"74","author":"Saketkoo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026020502573293900_bib65","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00296-009-0966-8","article-title":"The effects and mechanisms of mycophenolate mofetil on pulmonary arterial hypertension in rats","volume":"30","author":"Zheng","year":"2010","journal-title":"Rheumatol Int"},{"key":"2026020502573293900_bib66","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.autrev.2011.04.013","article-title":"B cells in systemic sclerosis: a possible target for therapy","volume":"10","author":"Bosello","year":"2011","journal-title":"Autoimmun Rev"},{"key":"2026020502573293900_bib67","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1002\/art.22847","article-title":"B cell infiltration in systemic sclerosis\u2013associated interstitial lung disease","volume":"56","author":"Lafyatis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2026020502573293900_bib68","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1752-699X.2010.00228.x","article-title":"Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease","volume":"6","author":"De Santis","year":"2012","journal-title":"Clin Respir J"},{"issue":"2","key":"2026020502573293900_bib69","first-page":"S17","article-title":"Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis","volume":"30","author":"Daoussis","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2026020502573293900_bib70","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.semarthrit.2014.09.002","article-title":"Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis","volume":"44","author":"Bosello","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2026020502573293900_bib71","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/kem357","article-title":"Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab","volume":"47","author":"McGonagle","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"2026020502573293900_bib72","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2026020502573293900_bib73","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12079-011-0122-6","article-title":"Possible strategies for anti-fibrotic drug intervention in scleroderma","volume":"5","author":"Leask","year":"2011","journal-title":"J Cell Commun Signal"},{"key":"2026020502573293900_bib74","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s004080000058","article-title":"Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases","volume":"179","author":"Reichenberger","year":"2001","journal-title":"Lung"},{"key":"2026020502573293900_bib75","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1093\/rheumatology\/keq241","article-title":"Clinical experience with bosentan and sitaxentan in connective tissue disease\u2013associated pulmonary arterial hypertension","volume":"49","author":"Valerio","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2026020502573293900_bib76","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.3899\/jrheum.110499","article-title":"Effect of bosentan on systemic sclerosis\u2013associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study","volume":"38","author":"Furuya","year":"2011","journal-title":"J Rheumatol"},{"key":"2026020502573293900_bib77","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/art.27466","article-title":"Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis","volume":"62","author":"Seibold","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2026020502573293900_bib78","first-page":"122","article-title":"The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review","volume":"31","author":"Muangchant","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2026020502573293900_bib79","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/annrheumdis-2011-200955","article-title":"Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis","volume":"71","author":"Khan","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2026020502573293900_bib80","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/annrheumdis-2015-eular.2281","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis: week 48 data from the faSScinate trial [abstract presented at meeting of the European League against Rheumatism (EULAR), Rome, Italy, June 10\u201313, 2015]","volume":"74","author":"Khanna","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026020502573293900_bib81","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1172\/JCI200419603","article-title":"Imatinib mesylate inhibits the profibrogenic activity of TGF-\u03b2 and prevents bleomycin-mediated lung fibrosis","volume":"114","author":"Daniels","year":"2004","journal-title":"J Clin Invest"},{"key":"2026020502573293900_bib82","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1002\/art.30548","article-title":"A one-year, phase I\/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis\u2013associated active interstitial lung disease","volume":"63","author":"Khanna","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2026020502573293900_bib83","first-page":"S-189","article-title":"Imatinib mesylate (Gleevec\u2122) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial","volume":"32","author":"Gordon","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2026020502573293900_bib84","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.2010.143974","article-title":"Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial","volume":"70","author":"Spiera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026020502573293900_bib85","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/j.1365-2133.2012.11186.x","article-title":"Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial","volume":"167","author":"Prey","year":"2012","journal-title":"Br J Dermatol"},{"key":"2026020502573293900_bib86","first-page":"560","article-title":"Multi-center, open-label, proof of concept study of imatinib mesylate demonstrates no benefit for the treatment of fibrosis in patients with early, diffuse systemic sclerosis [abstract]","volume":"62","author":"Distler","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2026020502573293900_bib87","doi-asserted-by":"crossref","first-page":"R144","DOI":"10.1186\/ar4606","article-title":"Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study","volume":"16","author":"Fraticelli","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2026020502573293900_bib88","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res"},{"key":"2026020502573293900_bib89","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40265-014-0335-0","article-title":"Nintedanib: first global approval","volume":"75","author":"McCormack","year":"2015","journal-title":"Drugs"},{"key":"2026020502573293900_bib90","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/annrheumdis-2014-207109","article-title":"Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis","volume":"75","author":"Huang","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026020502573293900_bib91","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"2026020502573293900_bib92","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","article-title":"Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis","volume":"590","author":"Oku","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"2026020502573293900_bib93","first-page":"L311","article-title":"Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level","volume":"276","author":"Gurujeyalakshmi","year":"1999","journal-title":"Am J Physiol"},{"key":"2026020502573293900_bib94","first-page":"652","article-title":"Pirfenidone and BIBF1120 suppress collagen synthesis in skin fibroblast from patients with systemic sclerosis [abstract]","volume":"65","author":"Yuko","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2026020502573293900_bib95","first-page":"235","article-title":"Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease","volume":"31","author":"Miura","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026020502573293900_bib96","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/annrheumdis-2015-eular.1913","article-title":"Safety and tolerability of pirfenidone in patients with systemic sclerosis\u2013associated interstitial lung disease: the LOTUSS study [abstract]","volume":"74","author":"Khanna","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026020502573293900_bib97","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1093\/rheumatology\/kev117","article-title":"Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis","volume":"54","author":"van Laar","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2026020502573293900_bib98","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/01.bor.0000434669.32150.ac","article-title":"Stem cell transplantation in systemic sclerosis","volume":"25","author":"van Laar","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"2026020502573293900_bib99","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"2026020502573293900_bib100","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/art.39021","article-title":"Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study","volume":"67","author":"Bernstein","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026020502573293900_bib101","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.rmed.2013.09.015","article-title":"Survival after lung transplantation in systemic sclerosis: a systematic review","volume":"107","author":"Khan","year":"2013","journal-title":"Respir Med"},{"key":"2026020502573293900_bib102","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/TP.0b013e3182845f23","article-title":"Outcomes in systemic sclerosis\u2013related lung disease after lung transplantation","volume":"95","author":"Sottile","year":"2013","journal-title":"Transplantation"},{"key":"2026020502573293900_bib103","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1513\/AnnalsATS.201503-177OC","article-title":"Lung transplantation in patients with scleroderma compared with pulmonary fibrosis: short and long-term outcomes in a single institution","volume":"13","author":"Crespo","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026020502573293900_bib104","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1513\/AnnalsATS.201512-806OC","article-title":"Lung transplant outcomes in systemic sclerosis with significant esophageal dysfunction: a comprehensive single center experience","volume":"13","author":"Miele","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026020502573293900_bib105","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3899\/jrheum.131251","article-title":"Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease\u2013related interstitial lung disease","volume":"41","author":"Saketkoo","year":"2014","journal-title":"J Rheumatol"},{"key":"2026020502573293900_bib106","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"2026020502573293900_bib107","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4172\/2161-1149.1000154","article-title":"Development of a composite outcome measure for systemic sclerosis related interstitial lung disease","volume":"5","author":"Volkmann","year":"2015","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2026020502573293900_bib108","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1016\/j.lpm.2014.08.002","article-title":"Interstitial lung disease in systemic sclerosis","volume":"43","author":"Wells","year":"2014","journal-title":"Presse Med"},{"issue":"2","key":"2026020502573293900_bib109","first-page":"S55","article-title":"Systemic sclerosis\u2013associated interstitial lung disease: proposed recommendations for future randomized clinical trials [review]","volume":"28","author":"Khanna","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2026020502573293900_bib110","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/art.1780370904","article-title":"Therapy for severe interstitial lung disease in systemic sclerosis: a retrospective study","volume":"37","author":"Steen","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2026020502573293900_bib111","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/art.30438","article-title":"Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease","volume":"63","author":"Roth","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2026020502573293900_bib112","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1183\/09059180.00001813","article-title":"Immunosuppression for interstitial lung disease in systemic sclerosis","volume":"22","author":"Cappelli","year":"2013","journal-title":"Eur Respir Rev"},{"key":"2026020502573293900_bib113","first-page":"1064","article-title":"Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study","volume":"35","author":"B\u00e9rezn\u00e9","year":"2008","journal-title":"J Rheumatol"},{"key":"2026020502573293900_bib114","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.semarthrit.2014.09.003","article-title":"Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders","volume":"44","author":"Iudici","year":"2015","journal-title":"Semin Arthritis Rheum"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/13\/11\/2045\/66768667\/annalsats_13_11_2045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/13\/11\/2045\/66768667\/annalsats_13_11_2045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:57:51Z","timestamp":1770278271000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/13\/11\/2045\/8449491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,1]]},"references-count":114,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,1]]},"published-print":{"date-parts":[[2016,11,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.201606-426fr","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,11]]},"published":{"date-parts":[[2016,11,1]]}}}